期刊
NATURE REVIEWS RHEUMATOLOGY
卷 16, 期 5, 页码 282-292出版社
NATURE RESEARCH
DOI: 10.1038/s41584-020-0395-3
关键词
-
类别
资金
- NIH [R03AR072182, R01AR074500, R01HL122593, K08AR073930]
- Riley Family Foundation
- Beatriz Snyder Foundation
- Rheumatology Research Foundation
- National Psoriasis Foundation
- Judith and Stewart Colton Center for Autoimmunity
- Damon Runyon Cancer Research Foundation [DRR-42-16]
- Searle Scholars Program [SSP-2016-1352]
- MINECO [SAF2017-90083-R]
In the past three decades, extraordinary advances have been made in the understanding of the pathogenesis of, and treatment options for, inflammatory arthritides, including rheumatoid arthritis and spondyloarthritis. The use of methotrexate and subsequently biologic therapies (such as TNF inhibitors, among others) and oral small molecules have substantially improved clinical outcomes for many patients with inflammatory arthritis; for others, however, these agents do not substantially improve their symptoms. The emerging field of pharmacomicrobiomics, which investigates the effect of variations within the human gut microbiome on drugs, has already provided important insights into these therapeutics. Pharmacomicrobiomic studies have demonstrated that human gut microorganisms and their enzymatic products can affect the bioavailability, clinical efficacy and toxicity of a wide array of drugs through direct and indirect mechanisms. This discipline promises to facilitate the advent of microbiome-based precision medicine approaches in inflammatory arthritis, including strategies for predicting response to treatment and for modulating the microbiome to improve response to therapy or reduce drug toxicity. Pharmacomicrobiomics studies investigating the effect of variations within the human gut microbiome on drugs have provided insights into therapeutics used for inflammatory arthritis, which could facilitate microbiome-based precision medicine approaches in rheumatology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据